UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

(Amendment No.)¹

GH Research PLC
(Name of Issuer)
Ordinary Shares, nominal value \$0.025 per share
(Title of Class of Securities)
G3855L106
(CUSIP Number)
December 31, 2021
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
□ Rule 13d-1(b)
□ Rule 13d-1(c)
⊠ Rule 13d-1(d)
The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in prior cover page.
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, <i>see</i> the <i>Notes</i>).

1	NAME OF REPORT	TING PERSON	
	Biotechnology	y Value Fund, L.P.	
2	CHECK THE APPR	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠ (b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF SHARES	5	SOLE VOTING POWER	
BENEFICIALLY		0 shares	
OWNED BY EACH	6	SHARED VOTING POWER	
REPORTING		4,840,750	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		0 shares	
	8	SHARED DISPOSITIVE POWER	
		4,840,750	
9	AGGREGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	4,840,750		
10		HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)	
	0.207		
12	9.3%	INC DEDCON	
12	TYPE OF REPORT	ING PERSOIN	
	PN		

	 			
1	NAME OF REPO	RTING PERSON		
	BVF I GP L			
2	CHECK THE API	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP		
			(b) □	
3	SEC USE ONLY			
4	CITIZENSHIP OF	R PLACE OF ORGANIZATION		
	Delaware			
NUMBER OF	5	SOLE VOTING POWER		
SHARES				
BENEFICIALLY		0 shares		
OWNED BY	6	SHARED VOTING POWER		
EACH				
REPORTING		4,840,750		
PERSON WITH	7	SOLE DISPOSITIVE POWER		
		0 shares		
	8	SHARED DISPOSITIVE POWER		
		4,840,750		
9	AGGREGATE AN	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	4,840,750			
10	CHECK BOX IF	THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		
		• • • • • • • • • • • • • • • • • • • •		
11	PERCENT OF CL	ASS REPRESENTED BY AMOUNT IN ROW (9)		
	9.3%			
12	TYPE OF REPOR	TING PERSON		
	00			
	1			

1	NAME OF REPORT	TING PERSON	
	Biotechnology	Value Fund II, L.P.	
2		ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠ (b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF SHARES BENEFICIALLY	5	SOLE VOTING POWER 0 shares	
OWNED BY EACH REPORTING	6	SHARED VOTING POWER 3,774,338	
PERSON WITH	7	SOLE DISPOSITIVE POWER 0 shares	
	8	SHARED DISPOSITIVE POWER 3,774,338	
9	AGGREGATE AM0 3,774,338	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
10		HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)	
12	TYPE OF REPORT PN	ING PERSON	

1	NAME OF REPORT	TING DERSON	
1	NAME OF REPORT	INGTERSON	
	BVF II GP LL	С	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ⊠		
			(b) 🗆
3	SEC USE ONLY		
4	CITIZENSHID OR I	PLACE OF ORGANIZATION	
4	CITIZENSIIII OKI	EACE OF ORGANIZATION	
	Delaware		
NUMBER OF	5	SOLE VOTING POWER	
SHARES			
BENEFICIALLY		0 shares	
OWNED BY EACH	6	SHARED VOTING POWER	
REPORTING		3,774,338	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		0 shares	
	8	SHARED DISPOSITIVE POWER	
		2 77 / 220	
9	AGGREGATE AMO	3,774,338 DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
J	AGGILLOTHE THAT	DENTI DENDE I CHILD DI ENCINALI GRITTA I ERGON	
	3,774,338		
10	CHECK BOX IF TH	IE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	DEDCENT OF CLA	CC DEDDECENTED DV AMOUNT IN DOW (0)	
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)	
	7.3%		
12	TYPE OF REPORT	ING PERSON	
	00		

1	NAME OF REPOR	TING PERSON	
	Biotechnolog	y Value Trading Fund OS LP	
2		ROPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵
			(b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	Cayman Islan	nds	
NUMBER OF SHARES	5	SOLE VOTING POWER	
BENEFICIALLY		0 shares	
OWNED BY EACH	6	SHARED VOTING POWER	
REPORTING		649,089	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
	_	0 shares	
	8	SHARED DISPOSITIVE POWER	
	A CODECATE AND	649,089	
9	AGGREGALE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
10	649,089	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	П
10	CHECK BOX IF 1.	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)	
11		100 KEI KESENTES DI TUNOUNI IN KOM (3)	
12	1.3% TYPE OF REPORT	TING PERSON	
	PN		

1	NAME OF REPORT	TING PERSON	
	BVF Partners	OS Ltd.	
2	CHECK THE APPR	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠ (b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR I	PLACE OF ORGANIZATION	
	Cayman Island	ds	
NUMBER OF SHARES BENEFICIALLY	5	SOLE VOTING POWER 0 shares	
OWNED BY EACH REPORTING	6	SHARED VOTING POWER 649,089	
PERSON WITH	7	SOLE DISPOSITIVE POWER 0 shares	
	8	SHARED DISPOSITIVE POWER 649,089	
9	AGGREGATE AMO	DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
10	CHECK BOX IF TH	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)	
12	TYPE OF REPORT	ING PERSON	

1	NAME OF REPORT	TING PERSON	
	BVF GP Hold	ings LLC	
2		COPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠ (b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF SHARES BENEFICIALLY	5	SOLE VOTING POWER 0 shares	
OWNED BY	6	SHARED VOTING POWER	
EACH	o o	SIMILE VOTING FOWER	
REPORTING		8,615,088	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		0 shares	
	8	SHARED DISPOSITIVE POWER	
		8,615,088	
9	AGGREGATE AMO	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	8,615,088		
10		HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)	
	40.007		
12	16.6% TYPE OF REPORT	INC DEDCON	
12	I I PE OF KEPORI	ING PERSON	
	00		

1	NAME OF REPORT	TING PERSON	
	BVF Partners	L.P.	
2	CHECK THE APPR	OPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠ (b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR I	PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF SHARES	5	SOLE VOTING POWER 0 shares	
BENEFICIALLY OWNED BY	6	SHARED VOTING POWER	
EACH		SHARED VOTING FOWER	
REPORTING		9,275,158	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		0 shares	
	8	SHARED DISPOSITIVE POWER	
		9,275,158	
9	AGGREGATE AMO	DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	9,275,158		
10		IE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)	
	.=		
- 12	17.8%	TNG PERCON	
12	TYPE OF REPORT	ING PERSUN	
	PN, IA		

1	NAME OF REPORT	TINC DEDCON		
1	NAME OF REPORT	ING PERSON		
	BVF Inc.			
2		OPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵	
2		OTRINIE BOX II A WEWDER OF A GROOT	(a) ⊡ (b) □	
			(6) —	
3	SEC USE ONLY	SEC USE ONLY		
4	CITIZENSHIP OR I	PLACE OF ORGANIZATION		
	Delaware	Lacy By yearning pay in p		
NUMBER OF SHARES	5	SOLE VOTING POWER		
BENEFICIALLY		0 shares		
OWNED BY	6	SHARED VOTING POWER		
EACH		SIRRED VOINGTOWER		
REPORTING		9,275,158		
PERSON WITH	7	SOLE DISPOSITIVE POWER		
		0 shares		
	8	SHARED DISPOSITIVE POWER		
		0.075.450		
	ACCDECATE AMO	9,275,158 DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
9	AGGREGALE AMO	JUNI BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	9,275,158			
10		IE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	П	
10		2 110 01 12 11 110 0111 11 110 11 (b) 2110 22 0 0 211 11 11 0 11 11 11 12 0	_	
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)		
	17.8%			
12	TYPE OF REPORT	ING PERSON		
	60			
	CO			

1	NAME OF DEDON	FINC DEDCOM	
1	NAME OF REPORT	TING PERSON	
	26 1 27 7		
	Mark N. Lam	•	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ⊠		
			(b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	**		
	United States	T	
NUMBER OF	5	SOLE VOTING POWER	
SHARES		0.1	
BENEFICIALLY		0 shares	
OWNED BY	6	SHARED VOTING POWER	
EACH		0.075.150	
REPORTING PERSON WITH		9,275,158	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		0 shares	
	8	SHARED DISPOSITIVE POWER	
	0	SHARED DISPOSITIVE POWER	
		9,275,158	
9	ACCRECATE AMO	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	AGGREGATE AM	OOM DEMENDER OWNED DI EACH REFORMING FERSON	
	9,275,158		
10		HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
			_
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)	
		· /	
	17.8%		
12	TYPE OF REPORT	ING PERSON	
	IN		

1	NAME OF REPORT	TING PERSON	
	Spike Loy		
2	CHECK THE APPR	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠ (b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR I	PLACE OF ORGANIZATION	
	United States		
NUMBER OF SHARES BENEFICIALLY	5	SOLE VOTING POWER 0 shares	
OWNED BY EACH REPORTING	6	SHARED VOTING POWER 0 shares	
PERSON WITH	7	SOLE DISPOSITIVE POWER 0 shares	
	8	SHARED DISPOSITIVE POWER 0 shares	
9	AGGREGATE AMO	DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	0 shares		
10	CHECK BOX IF TH	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)	
- 12	0%	TNG DEDGON	
12	TYPE OF REPORT	ING PERSON	
	IN		

Item 1(a). Name of Issuer:

GH Research PLC, an Irish company (the "Issuer").

Item 1(b). Address of Issuer's Principal Executive Offices:

28 Baggot Street Lower Dublin 2 DO2 NX43

Ireland

Item 2(a). Name of Person Filing

Item 2(b). Address of Principal Business Office or, if None, Residence

Item 2(c). Citizenship

Biotechnology Value Fund, L.P. ("BVF")

44 Montgomery St., 40th Floor San Francisco, California 94104

Citizenship: Delaware

BVF I GP LLC ("BVF GP")

44 Montgomery St., 40th Floor San Francisco, California 94104

Citizenship: Delaware

Biotechnology Value Fund II, L.P. ("BVF2")

44 Montgomery St., 40th Floor San Francisco, California 94104

Citizenship: Delaware

BVF II GP LLC ("BVF2 GP")

44 Montgomery St., 40th Floor San Francisco, California 94104

Citizenship: Delaware

Biotechnology Value Trading Fund OS LP ("Trading Fund OS")

PO Box 309 Ugland House Grand Cayman, KY1-1104

Cayman Islands

Citizenship: Cayman Islands

BVF Partners OS Ltd. ("Partners OS")

PO Box 309 Ugland House Grand Cayman, KY1-1104

Cayman Islands

Citizenship: Cayman Islands

BVF GP Holdings LLC ("BVF GPH")

44 Montgomery St., 40th Floor San Francisco, California 94104

Citizenship: Delaware

BVF Partners L.P. ("Partners") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

BVF Inc.

44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

Mark N. Lampert ("Mr. Lampert") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: United States

Spike Loy ("Mr. Loy") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: United States

Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."

Item 2(d). Title of Class of Securities:

Ordinary Shares, nominal value \$0.025 per share (the "Shares").

Item 2(e). CUSIP Number:

G3855L106

Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

	/x/	Not applicable.
(a)	//	Broker or dealer registered under Section 15 of the Exchange Act.
(b)	//	Bank as defined in Section 3(a)(6) of the Exchange Act.
(c)	//	Insurance company as defined in Section 3(a)(19) of the Exchange Act.
(d)	//	Investment company registered under Section 8 of the Investment Company Act.
(e)	//	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
(f)	//	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
(g)	//	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
(h)	//	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
(i)	//	A church plan that is excluded from the definition of an investment company under Section $3(c)(14)$ of the Investment Company Act.
(j)	//	Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
(k)	//	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: $_$

Item 4. Ownership

(a) Amount beneficially owned:

As of the close of business on December 31, 2021, (i) BVF beneficially owned 4,840,750 Shares, (ii) BVF2 beneficially owned 3,774,338 Shares and (iii) Trading Fund OS beneficially owned 649,089 Shares.

BVF GP, as the general partner of BVF, may be deemed to beneficially own the 4,840,750 Shares beneficially owned by BVF.

BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 3,774,338 Shares beneficially owned by BVF2.

Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 649,089 Shares beneficially owned by Trading Fund OS.

BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 8,615,088 Shares beneficially owned in the aggregate by BVF and BVF2.

Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 9,275,158 Shares beneficially owned in the aggregate by BVF, BVF2 and Trading Fund OS and held in a certain Partners managed account (the "Partners Managed Account"), including 10,981 Shares held in the Partners Managed Account.

BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 9,275,158 Shares beneficially owned by Partners.

Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 9,275,158 Shares beneficially owned by BVF Inc.

As of the close of business on December 31, 2021, Mr. Loy, a member of the Board of Directors of the Issuer and a Managing Director of Partners, did not beneficially own any Shares of the Issuer.

The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Shares owned by another Reporting Person. BVF GP disclaims beneficial ownership of the Shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the Shares beneficially owned by BVF2. Partners OS disclaims beneficial ownership of the Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the Shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Shares beneficially owned by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Accounts, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

(b) Percent of class:

The following percentages are based on 52,020,849 Shares outstanding which is the total number of Shares outstanding as disclosed in the Issuer's Unaudited Condensed Consolidated Interim Financial Statements filed on Form 6-K with the Securities and Exchange Commission on December 6, 2021.

As of the close of business on December 31, 2021, (i) BVF beneficially owned approximately 9.3% of the outstanding Shares, (ii) BVF2 beneficially owned approximately 7.3% of the outstanding Shares, (iii) Trading Fund OS beneficially owned approximately 1.3% of the outstanding Shares, (iv) BVF GP may be deemed to beneficially own approximately 9.3% of the outstanding Shares, (v) BVF2 GP may be deemed to beneficially own approximately 7.3% of the outstanding Shares, (vi) Partners OS may be deemed to beneficially own approximately 1.3% of the outstanding Shares, (vii) BVF GPH may be deemed to beneficially own approximately 16.6% of the outstanding Shares, (viii) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 17.8% of the outstanding Shares (less than 1% of the outstanding Shares are held in the Partners Managed Account) and (ix) Mr. Loy did not beneficially own any Shares.

- (c) Number of shares as to which such person has:
- (i) Sole power to vote or to direct the vote

See Cover Pages Items 5-9.

(ii) Shared power to vote or to direct the vote

See Cover Pages Items 5-9.

(iii) Sole power to dispose or to direct the disposition of

See Cover Pages Items 5-9.

(iv) Shared power to dispose or to direct the disposition of

See Cover Pages Items 5-9.

Item 5. Ownership of Five Percent or Less of a Class.

Not Applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

BVF GP, BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF2 GP, BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF2. Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by Trading Fund OS and held in the Partners Managed Account.

Item 7. Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or

Control Person.

Not Applicable.

Item 8. Identification and Classification of Members of the Group.

See Exhibit 99.1.

Item 9. Notice of Dissolution of Group.

Not Applicable.

Item 10. Certifications.

Not Applicable.

By:

/s/ Mark N. Lampert

Mark N. Lampert

President

SIGNATURE

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2022 BIOTECHNOLOGY VALUE FUND, L.P. BIOTECHNOLOGY VALUE TRADING FUND OS LP By: BVF Partners L.P., its investment manager BVF I GP LLC., its general partner BVF Inc., its general partner By: /s/ Mark N. Lampert Mark N. Lampert /s/ Mark N. Lampert Chief Executive Officer Mark N. Lampert President **BVF I GP LLC BVF GP HOLDINGS LLC** /s/ Mark N. Lampert By: Mark N. Lampert /s/ Mark N. Lampert Chief Executive Officer Mark N. Lampert Chief Executive Officer BIOTECHNOLOGY VALUE FUND II, L.P. BVF PARTNERS L.P. BVF II GP LLC, its general partner By: BVF Inc., its general partner /s/ Mark N. Lampert By: Mark N. Lampert /s/ Mark N. Lampert Chief Executive Officer Mark N. Lampert President **BVF II GP LLC** BVF INC. By: /s/ Mark N. Lampert By: /s/ Mark N. Lampert Mark N. Lampert Chief Executive Officer Mark N. Lampert President BVF PARTNERS OS LTD. /s/ Mark N. Lampert BVF Partners L.P., its sole member MARK N. LAMPERT BVF Inc., its general partner

/s/ Spike Loy

SPIKE LOY

18

Joint Filing Agreement

The undersigned hereby agree that the Statement on Schedule 13G dated February 14, 2022 with respect to the ordinary shares, no par value per share, of GH Research PLC, a public limited company incorporated in Ireland, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.

Dated: February 14, 2022 BIOTECHNOLOGY VALUE FUND, L.P. BIOTECHNOLOGY VALUE TRADING FUND OS LP BVF I GP LLC., its general partner By: BVF Partners L.P., its investment manager By: BVF Inc., its general partner /s/ Mark N. Lampert By: Mark N. Lampert By: /s/ Mark N. Lampert Chief Executive Officer Mark N. Lampert President **BVF I GP LLC BVF GP HOLDINGS LLC** By: /s/ Mark N. Lampert By: /s/ Mark N. Lampert Mark N. Lampert Chief Executive Officer Mark N. Lampert Chief Executive Officer BIOTECHNOLOGY VALUE FUND II, L.P. BVF PARTNERS L.P. BVF II GP LLC, its general partner By: BVF Inc., its general partner /s/ Mark N. Lampert Mark N. Lampert /s/ Mark N. Lampert Chief Executive Officer Mark N. Lampert President **BVF II GP LLC** BVF INC. /s/ Mark N. Lampert By: Mark N. Lampert /s/ Mark N. Lampert Chief Executive Officer Mark N. Lampert President BVF PARTNERS OS LTD. /s/ Mark N. Lampert BVF Partners L.P., its sole member MARK N. LAMPERT BVF Inc., its general partner

/s/ Spike Loy

SPIKE LOY

By:

/s/ Mark N. Lampert

Mark N. Lampert

President